The estimated Net Worth of Llp Abingworth is at least $188 Million dollars as of 28 January 2022. Llp Abingworth owns over 150,000 units of Vaxcyte stock worth over $149,219,121 and over the last 10 years Llp sold PCVX stock worth over $38,492,203.
Sign up
Llp Abingworth PCVX stock SEC Form 4 insiders trading
Llp has made over 12 trades of the Vaxcyte stock since 2014, according to the Form 4 filled with the SEC. Most recently Llp bought 150,000 units of PCVX stock worth $4,050,000 on 28 January 2022.
The largest trade Llp's ever made was buying 7,720,000 units of Vaxcyte stock on 21 December 2018 worth over $876,606,000. On average, Llp trades about 769,353 units every 120 days since 2014. As of 28 January 2022 Llp still owns at least 1,314,127 units of Vaxcyte stock.
You can see the complete history of Llp Abingworth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Llp Abingworth's mailing address?
Llp's mailing address filed with the SEC is 38 Jermyn St, St. James's, London SW1Y 6DT, UK.
Insiders trading at Vaxcyte
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... und Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
What does Vaxcyte do?
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
What does Vaxcyte's logo look like?
Complete history of Llp Abingworth stock trades at Chiasma Inc, Sientra Inc, Sierra Oncology Inc, Soleno Therapeutics Inc, Personalis Inc und Vaxcyte
Vaxcyte executives and stock owners
Vaxcyte executives and other stock owners filed with the SEC include:
-
Grant E. Pickering M.B.A.,
Co-Founder, CEO & Director -
Grant E. Pickering,
Co-Founder, CEO & Director -
James Wassil M.B.A., M.S.,
Chief Operating Officer -
Andrew L. Guggenhime M.B.A.,
Pres & CFO -
Harp Dhaliwal,
Sr. VP of Commercial Manufacturing & Supply Chain -
Mikhail Eydelman J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Jane Wright-Mitchell J.D., Pharm.D.,
Corp. Sec. & Chief Compliance Officer -
Janet Graesser,
VP of Corp. Communications & Investor Relations -
Dr. Ashish Khanna M.B.A., Ph.D.,
Co-Founder and Chief Bus. Officer -
Paul W. Sauer M.B.A., MBA,
Sr. VP of Process Devel. & Manufacturing -
Jane Wright-Mitchell J.D., Pharm.D.,
Gen. Counsel -
Kayo Chih,
Sr. Accounting Mang. -
Dr. Jeff Fairman,
Co-Founder & VP of Research -
Dr. Ashish Khanna Ph.D.,
Co-Founder and Chief Bus. Officer -
Jane Wright Mitchell,
General Counsel -
Grant Pickering,
CHIEF EXECUTIVE OFFICER -
Jacks Lee,
Director -
John Furey,
Director -
Teri Loxam,
Director -
Capital Management, L.P.Ra ...,
-
Heath Lukatch,
Director -
Elvia Cowan,
SVP, FINANCE -
Anne S Drapeau,
Director -
Robert Lorne Hopfner,
Director -
Patrick J Heron,
Director -
Group Holdings (Sbs) Adviso...,
-
Llp Abingworth,
10% owner -
Kurt Von Emster,
Director -
William J Newell,
Director -
Jeff Fairman,
VP, Research -
Paul Sauer,
SVP Process Dev, Manufacturing -
Halley E Gilbert,
Director -
Peter Hirth,
Director -
Jim Wassil,
CHIEF OPERATING OFFICER -
Carlos V Paya,
Director -
Michael E. Kamarck,
Director -
Harpreet S. Dhaliwal,
SVP Cml Mfg & Supply Chain -
Mikhail Eydelman,
SVP, GEN COUNSEL & CORP SEC